What is glucagon?
Glucagon is a naturally occurring peptide hormone with a central role in maintaining glucose availability and metabolic balance. It is produced primarily by alpha cells within the pancreatic islets and acts as an important physiological counterpart to insulin.
Human glucagon consists of 29 amino acids. When circulating glucose falls, glucagon signalling can increase hepatic glucose production, helping maintain an adequate supply of glucose to tissues. Its biology also extends beyond glucose regulation into amino-acid, lipid and energy metabolism.
Pancreatic alpha cells
Alpha cells are specialised endocrine cells located within the islets of Langerhans in the pancreas. Their principal hormonal product is glucagon.
Glucagon secretion is regulated by multiple signals, including circulating nutrients, neural inputs and communication between different pancreatic islet cells. Falling glucose concentrations can stimulate glucagon release, while insulin, somatostatin and nutrient-related signals can modify alpha-cell activity.
Alpha cells therefore participate in a coordinated endocrine system rather than functioning as an isolated glucose sensor.
Glucagon receptor
The glucagon receptor, abbreviated GCGR, is a G-protein-coupled receptor expressed particularly strongly in the liver.
When glucagon binds to GCGR on hepatocytes, receptor activation stimulates intracellular signalling pathways involving cyclic AMP (cAMP) and protein kinase A. These pathways alter enzyme activity and gene expression involved in metabolic regulation.
GCGR signalling is distinct from signalling through the GLP-1 and GIP receptors, although all three receptor systems are members of the class B family of G-protein-coupled receptors.
Glucose regulation
One of glucagon's best-established physiological functions is protecting against excessively low circulating glucose.
During fasting or other periods of reduced glucose availability, glucagon signals the liver to increase glucose output. This complements the actions of insulin, which generally promotes glucose uptake and storage when nutrients are abundant.
The balance between insulin and glucagon is therefore an important component of normal glucose homeostasis.
Hepatic signalling
The liver is a major target organ for glucagon. Glucagon-receptor activation can stimulate glycogenolysis, in which stored liver glycogen is broken down to make glucose available.
Glucagon also promotes hepatic gluconeogenesis, the production of glucose from non-carbohydrate precursors such as certain amino acids, lactate and glycerol.
Its hepatic effects extend into broader metabolic pathways involving amino-acid turnover and lipid metabolism. Modern research increasingly views glucagon as part of an interconnected liver-pancreas metabolic signalling system rather than simply a hormone that raises blood glucose.
Glucagon vs GLP-1
Glucagon and GLP-1 are related peptides because both originate from the precursor protein proglucagon, but they perform different physiological functions and activate different receptors.
Pancreatic alpha cells process proglucagon predominantly into glucagon. In intestinal L cells, different processing enzymes generate peptides including GLP-1.
Glucagon activates the glucagon receptor and has a major role in maintaining glucose availability through hepatic signalling. GLP-1 activates the GLP-1 receptor and participates in incretin signalling, including glucose-dependent insulin secretion, glucagon regulation, gastrointestinal function and appetite-related pathways.
Their shared molecular origin should therefore not be interpreted as meaning they are interchangeable hormones.
Glucagon vs GIP
Glucagon and GIP are also distinct metabolic hormones.
Glucagon is produced primarily by pancreatic alpha cells and acts strongly on the liver to regulate glucose availability.
GIP, or glucose-dependent insulinotropic polypeptide, is an incretin hormone released predominantly from intestinal K cells following nutrient intake. It activates the GIP receptor and can enhance glucose-dependent insulin secretion.
Glucagon and GIP therefore originate from different tissues, activate different receptors and have different principal physiological roles, although both participate in the wider regulation of metabolism.
Relationship to retatrutide research
Retatrutide is an investigational peptide designed to activate glucagon, GLP-1 and GIP receptors within a single molecule.
Its glucagon-receptor activity is scientifically significant because it introduces a metabolic signalling pathway not directly targeted by GLP-1/GIP dual agonists such as tirzepatide.
Researchers are studying how simultaneous activation of these three receptor systems influences metabolic physiology and how the effects of glucagon-receptor activation interact with GLP-1 and GIP receptor signalling.
However, findings involving retatrutide cannot be attributed to glucagon alone. Retatrutide is an engineered multi-receptor agonist with its own pharmacological properties, and evidence concerning it does not establish equivalent effects from endogenous glucagon or other glucagon-receptor agonists.
Frequently asked questions
What is glucagon?
Glucagon is a naturally occurring 29-amino-acid peptide hormone involved primarily in maintaining glucose availability and coordinating metabolic responses.
Where is glucagon produced?
Glucagon is produced primarily by pancreatic alpha cells located within the islets of Langerhans.
What does glucagon do?
One of its principal functions is signalling the liver to increase glucose availability, particularly during fasting or falling blood glucose.
Is glucagon the opposite of insulin?
They frequently produce opposing effects on glucose metabolism, but describing them simply as opposites is an oversimplification. They form part of an interconnected regulatory system involving numerous hormones and tissues.
Is glucagon the same as GLP-1?
No. Both can originate from the proglucagon precursor, but they are different peptides that activate different receptors and perform different physiological functions.
Is glucagon an incretin?
No. GLP-1 and GIP are the two principal recognised incretin hormones. Glucagon has a different physiological role.
Does retatrutide activate the glucagon receptor?
Yes. Retatrutide is being investigated as a multi-receptor agonist with activity at glucagon, GLP-1 and GIP receptors.
Does research on retatrutide demonstrate the effects of glucagon alone?
No. Retatrutide simultaneously engages three receptor systems, so its experimental and clinical findings cannot be attributed solely to glucagon-receptor signalling.
Scientific references
Scientific literature on glucagon includes extensive research into pancreatic alpha-cell biology, GCGR signalling, hepatic glycogenolysis, gluconeogenesis, amino-acid metabolism and the physiological relationship between glucagon and insulin. Research involving multi-receptor agonists such as retatrutide should be considered separately because these engineered molecules combine glucagon-receptor activity with additional GLP-1 and GIP receptor signalling.